The treatment of multiple myeloma cells with the BRD4 inhibitor JQ1 resulted in the loss of BRD4 at the majority (90%) of promoters and more than half (60%) of the enhancer regions with a preferential loss of BRD4 at super-enhancers of key oncogenic drivers such as c-MYC [26]. The gene discussed is BRD4; the disease is plasma cell myeloma.